Replies to post #47679 on PharmaCyte Biotech Inc (PMCB)

[rudygerner]

I'm not convinced that Novo Nordisk, Sanofi or Ely Lilly won't swoop in for the buyout; they know generic insulin is coming online as their patents expire, which will decrease their insulin revenue. Additionally, new technologies (i.e. PharmaCyte), which utilize cell encapsulation to treat diabetes via artificial pancreas, also pose a severe threat to future insulin revenue. The only way to stay in front is to own the technology exclusively. However, I would be more than happy with licensing, structured comparitively to how you described - only time will tell. Interesting conversation until a partnership/licensing agreement/buyout is announced.